Compare AUUD & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUUD | XRTX |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | Canada |
| Employees | 5 | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.3M |
| IPO Year | N/A | 2018 |
| Metric | AUUD | XRTX |
|---|---|---|
| Price | $1.42 | $2.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 662.3K | 9.9K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.35 |
| 52 Week High | $10.10 | $3.60 |
| Indicator | AUUD | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 41.83 |
| Support Level | $1.15 | $2.02 |
| Resistance Level | $1.46 | $2.40 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 81.82 | 18.63 |
Auddia Inc is a United States-based company. It operates through its proprietary AI platform for audio and is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. The group Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Its flagship audio superapp, called faidr, delivers multiple industry firsts, including: Ad-free listening on any AM/FM radio station, Content skipping across any AM/FM station, One-touch skipping of entire podcast ad breaks, and Integrated artist discovery experiences.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.